Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical stage biotechnology company, announced on Tuesday that the United States Patent and Trademark Office has issued a new patent for CM-101, Chemomab's first-in-class monoclonal antibody that neutralises CCL24, a novel disease target at the confluence of fibrosis and inflammation.
The new patent includes the use of CM-101 and sequence-related CCL24 antibodies to treat hepatic (liver) diseases. Presently, CM-101 is in a Phase two trial for the treatment of primary sclerosing cholangitis (PSC).
CM-101 is a monoclonal antibody that neutralises the soluble protein CCL24, a cytokine family member that can trigger self-reinforcing inflammatory and fibrotic pathways implicated in various serious progressive diseases.
NeoImmuneTech names new president and chief executive officer
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
Thermo Fisher Scientific unveils CorEvitas registry for generalized pustular psoriasis
Nektar Therapeutics commences Phase 2b rezpegaldesleukin clinical trial for alopecia areata
Innovent Biologics doses first participant in first-in-human phase one clinical trial of IBI3002
Ananda Developments secures CBD Drug Supply Agreement for endometriosis clinical trial
Trellus Health secures agreement with major US health plan for IBD management
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins